Literature DB >> 10741504

Metabolic genotype in relation to individual susceptibility to environmental carcinogens.

J A Indulski1, W Lutz.   

Abstract

Earlier research indicates that within the human population there are considerable differences in the response to the carcinogenic activity of environmental carcinogens. Genetic polymorphism associated with several variants of the gene products participating in the biotransformation of various xenobiotics (including carcinogens) found in human populations constitutes a major cause of those differences. Enzymes coded by different variants of the same gene can differ in their catalytic activities. Up to the present time, most information on the effect of genetic polymorphism on the individual's ability to activate or deactivate environmental carcinogenic xenobiotics, and the associated risk of cancer, has been collected from studies of cytochromes P-450 belonging to gene families CYP1, CYP2 and CYP3, and of glutathione S-transferases and N-acetyltransferases. As carcinogen metabolism comprises a chain of chemical reactions involving numerous enzymes and enzyme-coding genes, research performed hitherto is able to offer only a very limited explanation of the associations between genetic polymorphism and the individual's susceptibility to cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10741504     DOI: 10.1007/pl00007942

Source DB:  PubMed          Journal:  Int Arch Occup Environ Health        ISSN: 0340-0131            Impact factor:   3.015


  12 in total

1.  Cytochrome p450 2E1 polymorphisms and the risk of gastric cardia cancer.

Authors:  Lin Cai; Zong-Li Zheng; Zuo-Feng Zhang
Journal:  World J Gastroenterol       Date:  2005-03-28       Impact factor: 5.742

2.  Influence of CYP1A1, GST polymorphisms and susceptibility risk of chronic myeloid leukemia in Syrian population.

Authors:  Walid Al-Achkar; Ghassan Azeiz; Faten Moassass; Abdulsamad Wafa
Journal:  Med Oncol       Date:  2014-03-27       Impact factor: 3.064

3.  Interaction of major genes predisposing to hepatocellular carcinoma with genes encoding signal transduction pathways influences tumor phenotype and prognosis.

Authors:  Francesco Feo; Maddalena Frau; Rosa-Maria Pascale
Journal:  World J Gastroenterol       Date:  2008-11-21       Impact factor: 5.742

Review 4.  Molecular epidemiology of pancreatic cancer.

Authors:  Donghui Li; Li Jiao
Journal:  Int J Gastrointest Cancer       Date:  2003

5.  Gene polymorphisms of biotransforming enzymes (GSTs) and their association with lung cancer in the Slovakian population.

Authors:  T Matakova; M Sivonova; E Halasova; D Mistuna; A Dzian; P Berzinec; L Letkova; D Dobrota
Journal:  Eur J Med Res       Date:  2009-12-07       Impact factor: 2.175

6.  Polymorphisms of cytochrome P450 1A1, glutathione s-transferases M1 and T1 genes in Ouangolodougou (Northern Ivory Coast).

Authors:  Alfredo Santovito; Claudio Burgarello; Piero Cervella; Massimiliano Delpero
Journal:  Genet Mol Biol       Date:  2010-09-01       Impact factor: 1.771

Review 7.  New insights on the role of epigenetic alterations in hepatocellular carcinoma.

Authors:  Maddalena Frau; Claudio F Feo; Francesco Feo; Rosa M Pascale
Journal:  J Hepatocell Carcinoma       Date:  2014-06-12

8.  Association of The Common CYP1A1*2C Variant (Ile462Val Polymorphism) with Chronic Myeloid Leukemia (CML) in Patients Undergoing Imatinib Therapy.

Authors:  Samyuktha Lakkireddy; Sangeetha Aula; Swamy Avn; Atya Kapley; Raghunadha Rao Digumarti; Kaiser Jamil
Journal:  Cell J       Date:  2015-10-07       Impact factor: 2.479

9.  Functional PstI/RsaI polymorphism in CYP2E1 is associated with the development, progression and poor outcome of gastric cancer.

Authors:  Jin Feng; Xiaolin Pan; Junbo Yu; Zheng Chen; Hao Xu; Wael El-Rifai; Guoxin Zhang; Zekuan Xu
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

10.  CYP1A1 and GSTM1/T1 genetic variation in predicting risk for cerebral infarction.

Authors:  Kyung-Suk Moon; Hye-Jung Lee; Seung-Heon Hong; Hyung-Min Kim; Jae-Young Um
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 2.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.